Covering the operations of the oil and gas industry
General Interest
Refining & Processing
Drilling & Production
Exploration & Development
Pipelines & Transportation
Sections
General Interest
Refining & Processing
Drilling & Production
Exploration & Development
Pipelines & Transportation
LNG
Energy Transition
Industry Statistics
Members Only
Special
Webcasts
White Papers
Podcast
Magazine
Surveys
Research
Events
Submit an Article
Contact
About Us
Subscribe
Newsletters
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Affiliated Brands
OFFSHORE
ENERGYTECH
MICROGRID KNOWLEDGE
OGJ RESEARCH
Follow us on
http://www.facebook.com/ogjonline
https://www.linkedin.com/company/oil-&-gas-journal
http://twitter.com/ogjonline
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MeiraGTx Holdings plc - Ordinary Shares
(NQ:
MGTX
)
7.815
-0.195 (-2.43%)
Streaming Delayed Price
Updated: 11:13 AM EST, Jan 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MeiraGTx Holdings plc - Ordinary Shares
< Previous
1
2
Next >
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
November 13, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
November 10, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
October 07, 2025
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
August 14, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
May 13, 2025
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
May 13, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
May 09, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
March 13, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process
March 13, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
February 21, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations
January 22, 2025
MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company’s proprietary...
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
December 09, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
November 13, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
October 22, 2024
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
October 15, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
October 09, 2024
Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
August 12, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
August 12, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
May 09, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
April 24, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
April 18, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
March 14, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
February 13, 2024
MeiraGTx to receive $50 million milestone after initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of...
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
December 21, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
November 21, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
November 14, 2023
From
MeiraGTx
Via
GlobeNewswire
BestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential Transactions
October 31, 2023
Best Growth Stocks, a leading independent research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a...
Via
TheNewswire.com
MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities
October 30, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
October 24, 2023
Multiple Posters and Oral Presentations Highlight the Depth of Innovation from MeiraGTx’s Technology Platforms for Gene and Cell Therapy
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports Second Quarter 2023 Financial and Operational Results
August 10, 2023
From
MeiraGTx
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
